Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) said the National Medical Products Administration accepted drug registration applications for two drugs developed by two of its subsidiaries, a Monday bourse filing said.
The NMPA accepted the application of Polymyxin B sulfate for Injection of Guilin Pharmaceutical, while Shanghai Zhaohui Pharmaceutical had its application for Labetalol Hydrochloride Injection accepted by the regulator.
Polymyxin B sulfate for Injection is meant for the treatment of gram-negative bacterial infections while the Labetalol Hydrochloride Injection is for the treatment of severe hypertension.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。